 BARCELONA, Spain, April 28, 2021 PRNewswire -- Grifols MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS, a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, today announced it has signed an agreement with the government of Andorra through Andorra Development and Investment ADI to establish a global RDi hub to advance knowledge of the human immune system and investigate and develop new immune therapies. The planned facility, the Pyrenees Immunology Research Center PYIRC, will focus on developing treatments for immune system disorders that can result in diseases including autoimmunity disorders, cancer and emerging infectious diseases. 